Aurion Biotech, Inc. (Aurion Biotech) is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care. CAUTION: New Drug—Limited by Federal (or United States) law to investigational use.
| Website | https://aurionbiotech.com |
| Employees | 100 (76 on RocketReach) |
| Founded | 2022 |
| Industry | Biotechnology |
| Keywords | Clinical Stage Biotech, Eye Disease Treatment, Vision Restoration, Advanced Therapies, Ophthalmic Therapeutics, Ocular Surface Disease, Cell Therapy, Regenerative Medicine, Clinical Trials, Stem Cell Therapy, Rare Disease Treatment, Biotechnology, Translational Research, Drug Development, Pharmaceutical, Gene Therapy, New Drug Applications, Fda |
| Competitors | Roche, Pfizer, Amgen, Bristol Myers Squibb, AstraZeneca, Novartis, Gilead Sciences, Genentech, Regeneron, Sobi - Swedish Orphan Biovitrum AB (publ) +42 more (view full list) |
Looking for a particular Aurion Biotech employee's phone or email?
Arnaud Lacoste is the CEO of Aurion Biotech.
76 people are employed at Aurion Biotech.
Aurion Biotech is based in Seattle, Washington.